Drug major Lupin said it has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Tamiflu capsules, used in treating influenza.
The company has received final approval from the US drug regulator to market oseltamivir phosphate capsules, a generic version of Hoffman-La Roche Inc's Tamiflu capsules in strengths of 30 mg, 45 mg, and 75 mg, Lupin said in a statement.
Oseltamivir phosphate capsules are indicated for the treatment of influenza.
As per IMS MAT October 2017 data, the capsules clocked annual sales of around USD 467.8 million in the US market.
Shares of Lupin closed 0.46 per cent up at Rs 925.05 on the BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
